Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Brian G, Till"'
Autor:
Dong Hoon Lee, Wei Sun, Si Liu, Sang Yun Lee, Damian J Green, Ryan S Basom, Francisco Cervantes-Contreras, Feinan Wu, Richa Rai, Hamid R Mirzaei, Shyril O’Steen, Mazyar Shadman, Brian G Till
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Cell culture conditions during manufacturing can impact the clinical efficacy of chimeric antigen receptor (CAR) T cell products. Production methods have not been standardized because the optimal approach remains unknown. Separate CD4+ and
Externí odkaz:
https://doaj.org/article/a2627050cb1743209989e3f6b51c577f
Autor:
Hao Huang, Ling Peng, Bicheng Zhang, Brian G. Till, Yonghao Yang, Xiaojie Zhang, Lingdi Zhao, Xiaomin Fu, Tiepeng Li, Lu Han, Peng Qin, Lin Chen, Xiang Yan, Yang Liu, Wenkang Wang, Zhenlong Ye, Hongle Li, Quanli Gao, Zibing Wang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
PurposeThis study determined the efficacy of low-dose gemcitabine combined with programmed death-1 (PD-1) inhibitors for treating multiple malignancies, providing a cost-effective and safe treatment option.Study DesignThis study included 61 patients
Externí odkaz:
https://doaj.org/article/518d588a572e4de6bd0b5df295c880ed
Autor:
Yonghao Yang, Jun Li, Brian G. Till, Jun Wang, Bicheng Zhang, Hanping Wang, Hao Huang, Tiepeng Li, Quanli Gao, Hongle Li, Zibing Wang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Recently, combination regimens based on programmed cell death-1 (PD-1) blockade have become increasingly common in clinical practice for the treatment of cancer. Such combinations significantly improve efficacy, but treatment-related adverse events h
Externí odkaz:
https://doaj.org/article/3b5f2aaed70640a09d0abfee16714b6e
Autor:
Mazyar Shadman, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Filippo Milano, Ang Li, Alexandre V. Hirayama, Mohamed L. Sorror, Sindhu Cherian, Xueyan Chen, Ryan D. Cassaday, Brian G. Till, Ajay K. Gopal, Brenda M. Sandmaier, David G. Maloney, Cameron J. Turtle
Publikováno v:
Blood Advances, Vol 3, Iss 20, Pp 3062-3069 (2019)
Abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) is offered to selected patients after chimeric antigen receptor–modified T-cell (CAR-T) therapy. Lymphodepleting chemotherapy and CAR-T therapy have immunosuppressive and immunomodu
Externí odkaz:
https://doaj.org/article/377350884943460f8682f0b6563104d6
Autor:
Shumin Yuan, Ling Peng, Yuqing Liu, Brian G. Till, Xiang Yan, Jie Zhang, Liping Zhu, Huijuan Wang, Shaokai Zhang, Hongle Li, Quanli Gao, Zibing Wang
Publikováno v:
Cancer Immunology, Immunotherapy. 72:437-448
Anti-angiogenic drugs increase anti-tumor efficacy of immune checkpoint inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs remains unclear.We retrospectively analyzed efficacy and safety data from patients diagnosed with advanced o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c88fe80810368d6bb8557d5671d4bf9e
https://doi.org/10.1007/s00262-022-03259-5
https://doi.org/10.1007/s00262-022-03259-5
Autor:
Lorena Panaite, Qian 'Vicky' Wu, Jenna Voutsinas, Erin Mullane, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Stephen D. Smith, Ajay K. Gopal, Christina Poh, Lorenzo Iovino, Cameron J. Turtle, David G. Maloney, Brian G. Till, Jordan Gauthier, Mazyar Shadman
Publikováno v:
Leukemia & Lymphoma. 63:2918-2922
Cytopenias are important but less studied adverse events following chimeric antigen receptor-engineered T cell (CAR-T) therapy. In our analysis of patients with large cell lymphoma who received axicabtagene ciloleucel (axi-cel), we sought to determin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8594e7446a0ab642bd7ea2e7c6e921
https://doi.org/10.1080/10428194.2022.2095632
https://doi.org/10.1080/10428194.2022.2095632
Autor:
Barbara Savoldo, Gerhard Bauer, Brian G. Till, Peter Marks, Helen E. Heslop, Andrew D. Fesnak, Steven A. Feldman, Magdi Elsallab, Mohamed Abou-el-Enein
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c9f72194e95c7d56059a0c2e79e392
https://doi.org/10.1158/2643-3230.22543887
https://doi.org/10.1158/2643-3230.22543887
Autor:
Barbara Savoldo, Gerhard Bauer, Brian G. Till, Peter Marks, Helen E. Heslop, Andrew D. Fesnak, Steven A. Feldman, Magdi Elsallab, Mohamed Abou-el-Enein
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e38dcc00964eaa1f4ed05f6ec5f92e
https://doi.org/10.1158/2643-3230.c.6550449
https://doi.org/10.1158/2643-3230.c.6550449
Autor:
Brian G. Till, Stanley R. Riddell, David G. Maloney, Damian J. Green, Jeffrey K. Rossow, Lihua E. Budde, Barbara Pender, Ajay K. Gopal, Michael C. Jensen, Sang Yun Lee, Philip Olsen, Oliver W. Press, Gregory A. Rufener
CD20 is an attractive immunotherapy target for B-cell non-Hodgkin lymphomas, and adoptive transfer of T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD20 is a promising strategy. A theoretical limitation is that r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce1813c46f07193be5c47a664c6df0b3
https://doi.org/10.1158/2326-6066.c.6548539.v1
https://doi.org/10.1158/2326-6066.c.6548539.v1
Autor:
John M. Pagel, Oliver W. Press, Brenda Sandmaier, Brian G. Till, Ajay K. Gopal, Damian J. Green, K. Dane Wittrup, Kelly D. Orcutt, D. Scott Wilbur, Donald K. Hamlin, Ethan R. Balkin, Darrell R. Fisher, Mark D. Hylarides, Alexandra H. Hernandez, Margaret E. Nartea, Rosario Guel, Shyril O'Steen, Yukang Lin, Aimee L. Kenoyer, Johnnie J. Orozco
Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18cb196c04e590eb312858a4d9061fed
https://doi.org/10.1158/1535-7163.c.6542662
https://doi.org/10.1158/1535-7163.c.6542662